Clinical and microbiological features and outcomes of mucormycosis in critically ill patients.

[1]  A. Skiada,et al.  Epidemiology and Diagnosis of Mucormycosis: An Update , 2020, Journal of fungi.

[2]  C. Schwebel,et al.  Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy , 2020, Annals of Intensive Care.

[3]  H. Badali,et al.  Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. , 2019, The Lancet. Infectious diseases.

[4]  M. Kinzig,et al.  Influence of Sustained Low-Efficiency Dialysis Treatment on Isavuconazole Plasma Levels in Critically Ill Patients , 2019, Antimicrobial Agents and Chemotherapy.

[5]  A. Trampuz,et al.  A case report of cutaneous mucormycosis of the hand after minor trauma in a patient with acute myeloid leukaemia , 2019, Trauma case reports.

[6]  R. Wolfe,et al.  The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  D. Kontoyiannis,et al.  Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  T. Walsh,et al.  Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials , 2018, Antimicrobial Agents and Chemotherapy.

[9]  C. Beigelman-Aubry,et al.  Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  M. Hoenigl,et al.  Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy , 2018, Drug design, development and therapy.

[11]  A. Ibrahim,et al.  Challenges in the diagnosis and treatment of mucormycosis. , 2018, Medical mycology.

[12]  M. Bassetti,et al.  Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review , 2017, Infectious Diseases and Therapy.

[13]  P. Escribano,et al.  Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates , 2017, PloS one.

[14]  A. Limper,et al.  Pulmonary mucormycosis: clinical features and outcomes , 2017, Infection.

[15]  L. Scott,et al.  Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis , 2016, Drugs.

[16]  D. Kontoyiannis,et al.  Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  J. Perfect,et al.  Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. , 2016, The Lancet. Infectious diseases.

[18]  D. Galarza-Delgado,et al.  Clinical Features and Outcome of Mucormycosis , 2014, Interdisciplinary perspectives on infectious diseases.

[19]  G. Petrikkos,et al.  Epidemiology of mucormycosis in Europe. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  C. Lass‐Flörl,et al.  Mucormycosis--from the pathogens to the disease. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[21]  L. Pagano,et al.  ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[22]  M. Younes,et al.  A rare cause of gastrointestinal bleeding in the intensive care unit. Healthcare-associated mucormycosis. , 2014, Gastroenterology.

[23]  L. Pagano,et al.  Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries , 2013, Haematologica.

[24]  D. Kontoyiannis,et al.  Invasive fungal infections in patients with cancer in the Intensive Care Unit. , 2012, International journal of antimicrobial agents.

[25]  C. Elie,et al.  A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  D. Milner,et al.  Molecular Methods To Improve Diagnosis and Identification of Mucormycosis , 2011, Journal of Clinical Microbiology.

[27]  R. Goldberg,et al.  Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  K. Eva,et al.  Reassessing the methods of medical record review studies in emergency medicine research. , 2005, Annals of emergency medicine.

[30]  J. Steiner,et al.  Chart reviews in emergency medicine research: Where are the methods? , 1996, Annals of emergency medicine.